Company profile
Organon
OGN · NYSE
Share price · OGN
$13.68+0.26 (+1.94%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(11 total)
11Total Assets
7Approved
3Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Phosphodiesterase (multi-subtype)Small molecule | Asthma | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
Ezetimibe(Zetia) | Approved | Undisclosed / early pipeline · NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
| Approved | HMG-CoA reductaseSmall molecule | Atherosclerotic Cardiovascular Disease | |
mometasone furoate/formoterol fumarate(Dulera / Zenhale) | Approved | Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptorSmall molecule | Asthma |
| Approved | Cysteinyl leukotriene receptor 1 (CysLT1)Small molecule | Asthma | |
| Approved | Aryl hydrocarbon receptor · Undisclosed / early pipelineSmall molecule | Atopic DermatitisPsoriasis | |
AtovastatinNo recent activity | Phase 3 | HMG-CoA reductaseSmall molecule | Atherosclerotic Cardiovascular Disease |
MK0653A, ezetimibe (+) simvastatinNo recent activity | Phase 3 | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
vytorinNo recent activity | Phase 3 | HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinalSmall molecule | Atherosclerotic Cardiovascular Disease |
| Preclinical | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.